Integrating palliative care into management of advanced liver disease

  • Research type

    Research Study

  • Full title

    Integration of palliative care into the management of patients with advanced liver disease

  • IRAS ID

    193380

  • Contact name

    Hazel Woodland

  • Contact email

    hazel.woodland@uhbristol.nhs.uk

  • Sponsor organisation

    University of Bristol

  • Duration of Study in the UK

    1 years, 7 months, 1 days

  • Research summary

    Deaths from liver disease have increased dramatically in the United Kingdom over the past 20 years. Liver disease disproportionately affects young patients and those from socio-economically deprived populations, and is the third commonest cause of working age death in the UK.

    Advanced liver disease causes a range of unpleasant symptoms towards the end of life including itch, vomiting blood, fluid in the abdomen (ascites), jaundice, muscle weakness and confusion. Because liver disease can sometimes be cured (e.g by stopping drinking alcohol or liver transplantation) the point at which aggressive medical care becomes futile is more difficult to identify than in other diseases such as cancer.

    Despite evidence demonstrating the benefit of palliative and supportive care in advanced liver disease such care is rarely accessed. Research from the Royal Free Hospital demonstrated only 19% of patients assessed unsuitable for liver transplantation were referred to palliative care, on average only 4 days before death.

    Our research involves patients with advanced liver disease alongside their relatives and carers. Through interviewing patients and relative and carer interviews we will investigate the patient and family experience of advanced stage liver disease within the NHS. We will also investigate the impact of an early palliative and supportive care intervention in patients with advanced liver disease, in terms of its effect on mood, symptoms and quality of life.

    We will combine this information with wider epidemiological research looking at how UK patients with liver disease access healthcare in the last year of their life, and the current barriers to referring patients with liver disease to specialist palliative care in England.

    Ultimately we aim to design an easily transferable clinical framework through which palliative and supportive care can be integrated into the ongoing active management of patients with advanced liver disease.

  • REC name

    South Central - Hampshire B Research Ethics Committee

  • REC reference

    16/SC/0041

  • Date of REC Opinion

    25 Feb 2016

  • REC opinion

    Further Information Favourable Opinion